Abstract:Accumulating evidence suggests that the tumor immune microenvironment (TIME) significantly influences the response to immunotherapy, yet this complex relationship remains elusive. To address this issue, we developed TimiGP-Response (TIME Illustration based on Gene Pairing designed for immunotherapy Response), a computational framework leveraging single-cell and bulk transcriptomic data, along with response information, to construct cell-cell interaction networks associated with responders and estimate the role of immune cells in treatment response. This framework was showcased in triple-negative breast cancer treated with immune checkpoint inhibitors targeting the PD-1:PD-L1 interaction, and orthogonally validated with imaging mass cytometry. As a result, we identified CD8+ GZMB+ T cells associated with responders and its interaction with regulatory T cells emerged as a potential feature for selecting patients who may benefit from these therapies. Subsequently, we analyzed 3,410 patients with seven cancer types (melanoma, non-small cell lung cancer, renal cell carcinoma, metastatic urothelial carcinoma, hepatocellular carcinoma, breast cancer, and esophageal cancer) treated with various immunotherapies and combination therapies, as well as several chemo- and targeted therapies as controls. Using TimiGP-Response, we depicted the pan-cancer immune landscape associated with immunotherapy response at different resolutions. At the TIME level, CD8 T cells and CD4 memory T cells were associated with responders, while anti-inflammatory (M2) macrophages and mast cells were linked to non-responders across most cancer types and datasets. Given that T cells are the primary targets of these immunotherapies and our TIME analysis highlights their importance in response to treatment, we portrayed the pan-caner landscape on 40 T cell subtypes. Notably, CD8+ and CD4+ GZMK+ effector memory T cells emerged as crucial across all cancer types and treatments, while IL-17-producing CD8+ T cells were top candidates associated with immunotherapy non-responders. In summary, this study provides a computational method to study the association between TIME and response across the pan-cancer immune landscape, offering resources and insights into immune cell interactions and their impact on treatment efficacy.

Single-Cell Analysis of the Pan-Cancer Immune Microenvironment and scTIME Portal

Supplementary Table from Single-Cell Analysis of the Pan-Cancer Immune Microenvironment and Sctime Portal

TIMEx: tumor-immune microenvironment deconvolution web-portal for bulk transcriptomics using pan-cancer scRNA-seq signatures

Unravelling immune microenvironment features underlying tumor progression in the single-cell era

Comprehensive Study of Tumor Immune Microenvironment and Relevant Genes in Hepatocellular Carcinoma Identifies Potential Prognostic Significance

Immunosuppressive landscape in hepatocellular carcinoma revealed by single-cell sequencing

Recent developments in application of single-cell RNA sequencing in the tumour immune microenvironment and cancer therapy

Cytokine expression patterns: A single-cell RNA sequencing and machine learning based roadmap for cancer classification

MetaTiME Integrates Single-Cell Gene Expression to Characterize the Meta-Components of the Tumor Immune Microenvironment.

Unraveling the tumor immune microenvironment of lung adenocarcinoma using single-cell RNA sequencing

A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells

A single-cell pan-cancer analysis to show the variability of tumor-infiltrating myeloid cells in immune checkpoint blockade

Pan-cancer survey of lncRNA rewiring and functional alternation in tumor-infiltrating T cell by scLNC

TimiGP-Response: the pan-cancer immune landscape associated with response to immunotherapy

Advancements in technology for characterizing the tumor immune microenvironment

Single-Cell Profiling Reveals Heterogeneity of Primary and Lymph Node Metastatic Tumors and Immune Cell Populations and Discovers Important Prognostic Significance of CCDC43 in Oral Squamous Cell Carcinoma

Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond

Liver tumour immune microenvironment subtypes and neutrophil heterogeneity

MetaTiME: Meta-components of the Tumor Immune Microenvironment

Multiomic Spatial Phenotyping of the Tumor Immune Microenvironment at Single Cell Resolution

Profiling Tumor Immune Microenvironment of Non-Small Cell Lung Cancer Using Multiplex Immunofluorescence